Greenphire ClinCard System to Optimize Clinical Payment Tracking for Major University
King of Prussia, PA – Greenphire, the leading provider of payment technology for the clinical trials industry, today announced that Duke University has selected its ClinCard system to support financial data management and tracking in more than 3,000 clinical studies that the organization conducts each year. As one of the largest biomedical research enterprises in the U.S., Duke University will implement Greenphire's solution to automate the management of payments, and associated data, it makes to research participants annually.
Following an intensive review of the ClinCard system between Duke University's IT, information security, participant protection executives and Greenphire, it was determined that the solution could offer significant value in streamlining the tracking of payments to research participants in clinical trials and reduce manual workflow requirements, while enabling easily accessible, real-time payments to participants throughout a trial.
"We are delighted that Duke University has chosen Greenphire's ClinCard platform to automate its clinical payment systems,” said Samuel Whitaker, CEO, Greenphire. "We look forward to working with the team to implement the system and to demonstrate the results that can be achieved by using a centralized technology solution to make payments simpler, faster and easier to track."
The ClinCard System combines global electronic payment technology with real-time messaging functionality to automate payments made to trial participants. Payments are delivered through electronic transfers to a reloadable branded debit card. The patented solution enables participants to access their funds securely and in real-time, while sponsors are able to track and report all payments made from a web-based portal.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com or visit www.greenphire.com.
About Greenphire
Greenphire is the industry’s leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web?based payment technologies to help our clients improve operational efficiency, access clinical financial analytics, reduce costs, mitigate regulatory risks, increase participant retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
